INM176
PreclinicalSmall molecule
INM176 is one of 31 small molecule programs targeting Prostate Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoPhase 3
Acetylsalicylic Acid
BayerPhase 3
Xaluritamig
AmgenPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INM176. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMilton S. Hershey Medical Center